RepliCel Life Sciences Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was CAD 0.743228 million compared to CAD 4.07 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.13 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0428 USD | +4.99% | -.--% | -4.89% |
Apr. 18 | RepliCel Life Sciences Inc. Announces Secured Loan Agreement | CI |
2023 | RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-4.89% | 2.78M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- REPCF Stock
- News RepliCel Life Sciences Inc.
- RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022